Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 3/20 | 0.49 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.43 |
| ▸ | ADCY10 | Q96PN6 | 2/20 | 0.43 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.39 |
| ▸ | CCR2 | P41597 | 1/20 | 0.38 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.35 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.35 |
| ▸ | MGMT | P16455 | 1/20 | 0.35 |
| ▸ | DHFR | P00374 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18601620 | 1.00 | HTR6 (0.49) | HTR6HRH4ADCY10SLC2A1CCR2 | |
| SCHEMBL607201 | 0.86 | HRH4 (0.59) | HTR6HRH4ADCY10 | |
| SCHEMBL1774656 | 0.85 | HTR6 (0.64) | HTR6HRH4ADCY10 | |
| SCHEMBL1774927 | 0.80 | HTR6 (0.44) | HTR6HRH4ADCY10SLC2A1CCR2 | |
| SCHEMBL1775372 | 0.80 | HRH4 (0.52) | HRH4 | |
| SCHEMBL1773989 | 0.80 | HTR6 (0.44) | HTR6HRH4ADCY10SLC2A1CCR2 | |
| SCHEMBL18601615 | 0.74 | NUDT1 (0.41) | HRH4DHFR | |
| SCHEMBL1774078 | 0.74 | NUDT1 (0.41) | HRH4DHFR | |
| SCHEMBL1774881 | 0.74 | HRH4 (0.49) | HRH4 | |
| SCHEMBL1775189 | 0.72 | HTR6 (0.48) | HTR6HRH4ADCY10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1966162-B1 | PYRIMIDINE DERIVATIVES | ZIARCO PHARMA LTD (GB) | 2017-03-15 | — | — | EP | disclosed |
| US-7943628-B2 | Pyrimidine derivatives | PFIZER LIMITED (GB) | 2011-05-17 | — | — | US | disclosed |
| EP-1966162-A2 | PYRIMIDINE DERIVATIVES | Pfizer Limited (GB) | 2008-09-10 | — | — | EP | disclosed |
| US-20070185075-A1 | Pyrimidine derivatives | PFIZER LIMITED | 2007-08-09 | — | — | US | disclosed |
| WO-2007072163-A2 | PYRIMIDINE DERIVATIVES | PFIZER LIMITED (GB) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185075-A1 | Pyrimidine derivatives | TYMS, DPYD, TYMP | HTR6 2234/4885HRH4 184/4885ADCY10 2130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.